Gadeta
Gadeta aims to develop a cancer treatment for all types of tumors
home
Gadeta B.V., a Clade Therapeutics Inc. company, is a clinical stage company developing innovative cell therapy treatments based on γδ T cell receptors for targeting tumors.
Gadeta is about developing lifesaving drugs that work by tapping into a new universe of cancer targets present on most tumors. We want to treat every cancer patient.
Our mission is to deliver transformative medicines for any type of cancer.
6 March 2023
Gadeta to Attend/Present Data on Tumor-Specific Cell Therapies at Leading Scientific Conferences. Read more
2 October 2023
Clade Therapeutics Announces the Acquisition of Gadeta B.V. Read more
2 December 2022
Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta TCR ImmTAC for Solid Tumors. Read more
1 December 2022
Gadeta to Attend/Present Data on Tumor-Specific Cell Therapies at Leading Scientific Conferences - December. Read more
2 November 2022
Gadeta to Present Data on Tumor-Specific Cell Therapies at Leading Scientific Conferences. Read more
20 October 2022
Gadeta Appoints Scientific Advisory Board and Provides Business Update Read more here
4 May 2022
Gadeta to Attend Upcoming Business and Investor Conferences Read more here
28 March 2022
Gadeta to Present Data on Tumor-Specific Cell Therapies at Leading Scientific Conferences. Read more here
16 March 2022
Gadeta to Present at Oppenheimer Annual Healthcare Conference. Read more here
15 March 2022
Gadeta announces significant progress in advancing pipeline and TEG platformdevelopment Read more here
6 July 2021
Gadeta announced the dosing of the first patient with GDT002. Read more here
19 July 2018
Kite and Gadeta announce strategic collaboration to advance γδ T cell receptor Technology for solid tumors. Read more here
12 April 2022
Gadeta presents poster at AACR. Read more